BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HRS-4729 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HRS-4729\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07690826-187@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HRS-4729: Phase 2 readout est. (NCT07690826)
DESCRIPTION:HRS-4729\, phase 2\, Obesity.\nStudy: A Study to Evaluate the E
 fficacy and Safety of HRS-4729 Injection in Obesity\nEstimated primary com
 pletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hrs-4729#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07690826
URL:https://assetmemo.bio/drug/hrs-4729#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07807059-187@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:HRS-4729: Phase 1 readout est. (NCT07807059)
DESCRIPTION:HRS-4729\, phase 1\, Obesity.\nStudy: A Single-Dose Pharmacokin
 etic Study of HRS-4729 Injection in Healthy Participants and Patients With
  Renal Impairment\nEstimated primary completion: 15 March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hrs-4729#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07807059
URL:https://assetmemo.bio/drug/hrs-4729#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843862-187@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:HRS-4729: Phase 2 readout est. (NCT07843862)
DESCRIPTION:HRS-4729\, phase 2.\nStudy: A Study of HRS-4729 Injection in Pa
 rticipants With Type 2 Diabetes\nEstimated primary completion: April 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/hrs-4729#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07843862
URL:https://assetmemo.bio/drug/hrs-4729#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07660848-187@assetmemo.bio
DTSTAMP:20261121T005705Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:HRS-4729: Phase 2 readout est. (NCT07660848)
DESCRIPTION:HRS-4729\, phase 2.\nStudy: A Study of HRS-4729 Injection and H
 RS9531 Injection in Participants With Metabolic Dysfunction-Associated Ste
 atohepatitis\nEstimated primary completion: March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/hrs-4729#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07660848
URL:https://assetmemo.bio/drug/hrs-4729#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
